Key facts
- It has raised $28.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, Oriental Fortune Capital, SDIC Unity Capital, Proxima Ventures (China), Xiamen C&D Corporation — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Trulive Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Trulive Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trulive Medical
Manufacturer of medical instruments designed to cure structural heart diseases. The company develops bicuspid valve substitute solutions for the four major disease areas of heart valve disease, heart failure, peripheral artery disease, and coronary artery disease, thereby providing medical providers with effective technology and equipment support.
- Sector
- Healthcare
- HQ
- Nantong, China
- Founded
- 2019
- Employees
- 200
- Website
- trulive.cn/
- Ownership
- Privately Held (backing)
Trulive Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trulive Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trulive Medical in its N-PORT filings yet. We sweep new filings monthly.